Evidence map›Paper›PMID 34151763›Full record

ReviewCurrent neuropharmacology2021

Current Clinical Psychopharmacology in Borderline Personality Disorder.

Antonio Del Casale, Luca Bonanni, Paride Bargagna, Francesco Novelli, Federica Fiaschè, Marco Paolini, Francesca Forcina, Gaia Anibaldi, Francesca Natalia Cortese, Alessia Iannuccelli and 5 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Antonio Del CasaleDepartment of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Luca BonanniDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Paride BargagnaDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Francesco NovelliDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Federica FiaschèDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Marco PaoliniDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Francesca ForcinaDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Gaia AnibaldiDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Francesca Natalia CorteseDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Alessia IannuccelliDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Barbara AdrianiDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Roberto BrugnoliDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Paolo GirardiDepartment of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Joel ParisMcGill University, SMBD-Jewish General Hospital, Institute of Community and Family Psychiatry, Montreal, Canada.
Maurizio PompiliDepartment of Neuroscience, Mental Health, and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University, Rome, "Sant'Andrea" University Hospital, Rome, Italy.
Azienda Ospedaliera Sant'Andrea · ITJewish General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with Borderline Personality Disorder (BPD) manifest affective and behavioral symptoms causing personal distress, relationship difficulties, and reduced quality of life with global functioning impairment, mainly when the disease takes an unfavorable course. A substantial amount of healthcare costs is dedicated to addressing these issues. Many BPD patients receive medications, mostly those who do not respond to psychological interventions.

objectiveOur aim was to assess the efficacy of the most used strategies of pharmacological interventions in BPD with a comprehensive overview of the field.

methodsWe searched the PubMed database for papers focused on the most used psychotropic drugs for BPD. We included randomized controlled trials and open studies in adult patients with BPD, focusing on the efficacy and tolerability of single classes of drugs with respect to specific clinical presentations that may occur during the course of BPD.

resultsSpecific second-generation antipsychotics (SGAs) or serotonergic antidepressants can be effective for different core symptoms of BPD, mainly including mood symptoms, anxiety, and impulse dyscontrol. Some atypical antipsychotics can also be effective for psychotic and dissociative symptoms. Specific antiepileptics can be useful in some cases in treating different BPD symptoms, mainly including mood instability, impulsiveness, and anger.

conclusionNo medication is currently approved for BPD, and clinicians should carefully assess the benefits and risks of drug treatment. Further studies are needed to identify specific personalized treatment strategies, also considering the clinical heterogeneity and possible comorbidities of BPD.

Indexed as

Antipsychotic AgentsBorderline Personality DisorderPsychopharmacologyAdultAntidepressive AgentsHumansQuality of LifeAntidepressive AgentsAntipsychotic Agentsaffective instabilityangerantidepressants.atypical antipsychoticsBorderline personality disorderdrug treatmentimpulsivenessmood stabilizers

Identifiers

PMID34151763
PMCPMC8977633
OpenAlexW3176832694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.